Akriveia Therapeutics' Aklusion™ Platform for Tumor-Targeting Cancer Immunotherapies to be Featured in Poster Presentation at the Society for Immunotherapy of Cancer's (SITC) 32nd Annual Meeting

Tuesday, November 7, 2017 Cancer News
Email Print This Page Comment bookmark
Font : A-A+

PRINCETON, N.J., Nov. 7, 2017 /PRNewswire/ -- Akriveia Therapeutics Inc., an immuno-oncology focused biotechnology

company, today announced its Aklusion™ platform for tumor-targeting cancer immunotherapies will be featured in a poster presentation at the Society for Immunotherapy of Cancer's (SITC) 32nd Annual Meeting, November 10-12,
2017
, at Gaylord National Hotel & Convention Center in National Harbor, MD.

The poster's authors include scientists from the laboratories of Professor John Williams of the Beckman Research Institute at the City of Hope and Professor Ulrich Rodeck at Thomas Jefferson University, along with Dr. Margaret Karow, Senior Vice President of Drug Discovery and Preclinical Development at Akriveia Therapeutics.

Information about the poster presentation is:

Poster Title: Rational Design of Immuno-Oncology Biologics with Improved Safety and Efficacy

Poster Number: P466

Poster Session: Saturday November 11th 12:30pm-2:00pm and 6:30pm-8:00pm

About Akriveia Therapeutics

Akriveia Therapeutics is pursuing the discovery and development of next generation cancer immunotherapies. Akriveia believes its new agents offer the promise of a more efficacious and safer approach to harness a patient's own immune system to fight cancer. Akriveia was founded on the pioneering work of Professor John Williams at City of Hope and Professor Ulrich Rodeck at Thomas Jefferson University, experts in the fields of bioengineering and cancer therapeutic discovery. The company is backed by leading life science investor FPrime Capital Partners.

 

View original content:http://www.prnewswire.com/news-releases/akriveia-therapeutics-aklusion-platform-for-tumor-targeting-cancer-immunotherapies-to-be-featured-in-poster-presentation-at-the-society-for-immunotherapy-of-cancers-sitc-32nd-annual-meeting-300551043.html

SOURCE Akriveia Therapeutics



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store